What Do Value Assessments Miss? Rethinking Value Using New Health Economics Evidence.

Dr. Patti Peeples, CEO and Founder of HealthEconomics.Com, recently sat down with Dr. Anupam Jena, Scientific Advisor, Precision Xtract, to discuss his latest research that expands the definition and measurement of value of novel therapies by using new health economics evidence. Continue Reading

Real-world evidence and value-based contracting – swipe left or swipe right?

As biopharma makes the shift toward a personalized healthcare system, it is also transitioning towards a pipeline full of innovative, high-cost therapies. We are moving to a value-based system, with two of the biggest ideas for this decade becoming more… Continue Reading

CVS Caremark’s foray into cost-effectiveness analysis raises questions about the future of prescription medicines in America

Written By: Americans spend more on prescription drugs than anyone else in the world. In a move to address this, CVS Caremark announced in August that it would allow self-funded insurers to exclude from their plan any drug launched at… Continue Reading

Optimized Value Analytics – The Next Frontier for Payers and Pharma?

By Caitlin Rothermel, MA, MPHc Introduction If you’ve been following the health economics industry for the past few years, you’ve heard about value-based pricing agreements between payers and the pharmaceutical industry. With value-based approaches, payment is linked directly to real-world treatment… Continue Reading